 |
    |
Juq-123 ❲High-Quality · 2026❳
Figure 2a displays a well‑saturated P‑E hysteresis loop at 300 K with Pₛ ≈ 9 µC cm⁻², coercive field E_c ≈ 120 kV cm⁻¹, and remanent polarization Pr ≈ 7.5 µC cm⁻². The loops retain their shape up to 425 K, above which the material transitions to a paraelectric phase (T_c ≈ 438 K).
Dielectric spectroscopy reveals low loss (tan δ < 0.02) across 1 kHz–10 MHz (Fig. 2b) and a high breakdown strength of 3 MV cm⁻¹, exceeding most organic ferroelectrics. JUQ-123
Fatigue testing shows > 10¹² switching cycles with < 5 % degradation in Pr, indicating excellent endurance. Figure 2a displays a well‑saturated P‑E hysteresis loop
The target molecule, 4‑(3‑aminopropyl)‑2,3‑dihydro‑1,4‑quinoxaline (APQ), was synthesized via a two‑step condensation of o‑phenylenediamine with 4‑formylbenzoic acid followed by reductive amination with 3‑aminopropanal. The APQ ligand was subsequently coordinated to a ZrCl₄ precursor in a solvothermal reaction (180 °C, 48 h, DMF:ethanol = 3:1). Crystallization yielded blue‑green platelets of JUQ‑123. Storage & Indexing
DFT calculations yield a Berry‑phase polarization of 8.8 µC cm⁻², in excellent agreement with experiment. The energy barrier for the cooperative proton transfer is 0.13 eV per proton, enabling rapid polarization reversal at modest fields. MD simulations at 300 K reveal continuous proton hopping along the hydrogen‑bond network, sustaining the polar order (Fig. 3).
Electronic structure analysis shows a wide bandgap of 3.1 eV, consistent with the observed low leakage currents.
Treatment of AML cell lines with JUQ-123 resulted in a dose-dependent reduction in cellular viability. The EC50 values ranged from 15 nM to 80 nM across the tested lines. Notably, JUQ-123 induced profound apoptosis (Annexin V+/PI+), reaching 78% in MOLM-13 cells at 100 nM after 48 hours. In primary AML samples, including those with FLT3-ITD and TP53 mutations, JUQ-123 significantly reduced colony-forming unit (CFU) capacity compared to normal CD34+ hematopoietic stem cells, indicating a therapeutic window.